KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Depreciation & Amortization (CF) (2016 - 2025)

Sarepta Therapeutics has reported Depreciation & Amortization (CF) over the past 15 years, most recently at $5.3 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $5.3 million for Q4 2025, down 49.76% from a year ago — trailing twelve months through Dec 2025 was $44.5 million (up 18.02% YoY), and the annual figure for FY2025 was $44.5 million, up 18.02%.
  • Depreciation & Amortization (CF) for Q4 2025 was $5.3 million at Sarepta Therapeutics, down from $18.4 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for SRPT hit a ceiling of $18.4 million in Q3 2025 and a floor of $5.3 million in Q4 2025.
  • Median Depreciation & Amortization (CF) over the past 5 years was $10.5 million (2021), compared with a mean of $10.3 million.
  • Peak annual rise in Depreciation & Amortization (CF) hit 88.15% in 2025, while the deepest fall reached 49.76% in 2025.
  • Sarepta Therapeutics' Depreciation & Amortization (CF) stood at $10.1 million in 2021, then rose by 4.02% to $10.6 million in 2022, then increased by 7.76% to $11.4 million in 2023, then dropped by 8.06% to $10.5 million in 2024, then plummeted by 49.76% to $5.3 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $5.3 million (Q4 2025), $18.4 million (Q3 2025), and $10.8 million (Q2 2025) per Business Quant data.